BIRC3 and B-cell chronic lymphocytic leukemia: Moreover, the CLL14 phase III randomized trial, evaluating front-line treatment with venetoclax plus obinutuzumab versus Chl-O in CLL, has shown poor outcomes in BIRC3 mutated patients treated with Chl-O, with a median PFS of 16.8 months [35,74].